Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy
Therapeutic dendritic cell (DC) cancer vaccines rely on the immune system to eradicate tumour cells. Although tumour antigen-specific T cell responses have been observed in most studies, clinical responses are fairly low, arguing for the need to improve the design of DC-based vaccines. The incorpora...
Main Author: | Mouldy Sioud |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/2/176 |
Similar Items
-
Immunotherapies for the Treatment of Uveal Melanoma—History and Future
by: Timo E. Schank, et al.
Published: (2019-07-01) -
Cholangiocarcinoma in the Era of Immunotherapy
by: Eleni Manthopoulou, et al.
Published: (2023-06-01) -
Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy
by: Robert D. Carlson, et al.
Published: (2020-04-01) -
Modern T cell technologies for immunotherapy of solid tumors
by: M. S. Kuznetsova, et al.
Published: (2023-04-01) -
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream
by: Luana Calabrò, et al.
Published: (2024-01-01)